A Phase 4 interventional study of Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) and Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) in Macular Degeneration, sponsored by Bayer. Completed at 39 sites in 8 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-08.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 17th largest by enrollment, is one of 6 that started in 2015, is one of 27 in phase 4, and was the 38th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 6 started in 2015.
This study's enrollment of 287 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
30 studies in Macular Degeneration by Bayer: none open now, 1 under way, none of them phase 3. Of 29 finished, 10 (34%) have results posted.
Among the 30 studies in Macular Degeneration by Bayer, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2015, is one of 5 in phase 4, and was the 15th registered.
Bayer’s Macular Degeneration studies by the year they started, since 2008.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Bayer’s 30 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.
The T\&E dosing regimen for nAMD has emerged as a preferred regimen for many treating physicians aiming at maximizing outcomes by proactively treating the subject at each visit and by extending the treatment interval (if extension criteria are met), thus limiting visits, monitoring, and injections.
To this day, there is limited evidence available addressing the question of what are useful intervals for treating and monitoring, how do they differ among subjects, and how are retreatment criteria applied to achieve long-term desirable outcomes in real-life practice. This study is designed to evaluate the optimal use, efficacy, and safety of the T\&E regimen with intravitreal aflibercept in subjects with nAMD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Early-start T\&E arm: test group, early treatment individualization
Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Late-start T\&E arm; per label, control group, treatment individualization after Year 1
Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
Change in BCVA as Measured by the ETDRS Letter Score
BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.
Time frame: From Week 16 to Week 104
Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline
Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.
Time frame: at Week 104
Change in BCVA From Baseline to Week 52, Baseline to Week 104, and Week 16 to Week 52
BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.
Time frame: from baseline to Week 52, baseline to Week 104, and Week 16 to Week 52
Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline
Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.
Time frame: At week 52
Percentage of Participants Gained 3-line at Week 52 and Week 104 Compared With Baseline
Participants gained 3 lines (15 letters) in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.
Time frame: At Week 52 and Week 104
Change in Central Retinal Thickness (CRT)
CRT were evaluated using spectral domain Optical coherence tomograph (OCT).
Time frame: From baseline to Week 52, baseline to Week 104, Week 16 to Week 52, and Week 16 to Week 104
Number of Study Drug Injections From Baseline to Week 52 and Baseline to Week 104
Time frame: At Week 52 and Week 104
Duration of Last Treatment Interval
Time frame: Early-Start T&E: from week 16 up to Week 104 or early termination; Late-Start T&E: From end of Year 1 up to Week 104 or early termination
Percentage of Participants Requiring Retreatment at 8 Weeks, 10 Weeks, 12 Weeks, 14 Weeks, and 16 Weeks as the Last Treatment Interval
Time frame: at 8 weeks, 10 weeks, 12 weeks, 14 weeks, and 16 weeks
This study was conducted from 19-Nov-2015 (First Patient First Visit) to 26-Apr-2019 (Last Patient Last Visit).
| Milestone | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| Started | 135 | 136 |
| Completed treatment | 120 | 117 |
| Completed | 119 | 117 |
| Not completed | 16 | 19 |
| Withdrew: Adverse event | 4 | 6 |
| Withdrew: Death | 3 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Other reasons | 3 | 1 |
| Withdrew: Discontinued during followup | 1 | 0 |
BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.
| Letters correctly read | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| Change in BCVA as Measured by the ETDRS Letter Score | -2.1 ± 11.4 | -0.4 ± 8.4 |
Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.
| Percentage | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline | 93.4 | 96.2 |
BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.
| Letters | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| From baseline to Week 52 | 7.8 ± 9.4 | 10.2 ± 9.3 |
| From baseline to Week 104 | 4.3 ± 13.4 | 7.9 ± 11.9 |
| Week 16 | 66.7 ± 13.0 | 69.6 ± 11.6 |
| From Week 16 to Week 52 | 1.3 ± 6.4 | 2.0 ± 5.3 |
Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.
| Percentage | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline | 100.0 | 100.0 |
Participants gained 3 lines (15 letters) in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.
| Percentage | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| Week 52 | 19.8 | 27.9 |
| Week 104 | 18.9 | 22.1 |
CRT were evaluated using spectral domain Optical coherence tomograph (OCT).
| μm | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| From baseline to Week 52 | -164.9 ± 117.3 | -167.1 ± 117.1 |
| From baseline to Week 104 | -161.6 ± 135.6 | -158.6 ± 125.1 |
| Week 16 | 321.4 ± 93.4 | 322.5 ± 104.0 |
| From Week 16 to Week 52 | -28.5 ± 56.3 | -28.7 ± 54.0 |
| From Week 16 to Week 104 | -25.1 ± 68.9 | -20.2 ± 70.0 |
| injections | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| Week 52 | 7.1 ± 0.8 | 8.0 ± 0.2 |
| Week 104 | 12.0 ± 2.3 | 13.0 ± 1.8 |
| Weeks | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| Duration of Last Treatment Interval | 11.5 ± 3.7 | 11.4 ± 3.7 |
| percentage | Early-start T&E Arm | Late-start T&E Arm |
|---|---|---|
| <8 weeks | 5.7 | 7.7 |
| 8 weeks | 27.4 | 29.8 |
| 10 weeks | 19.8 | 10.6 |
| 12 weeks | 8.5 | 13.5 |
| 14 weeks | 8.5 | 11.5 |
| 16 weeks | 25.5 | 25.0 |
| >16 weeks | 4.7 | 1.9 |
Collected over Treatment-emergent adverse events (TEAEs) were AEs that started after the first application of aflibercept up to 30 days after last study drug Injection in the study. TEAEs were collected from Week 0 till End of study/Week 104 or early termination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Early-start T&E Arm | 3/135 (2.2%) | 29/135 (21.5%) | 93/135 (68.9%) |
| Late-start T&E Arm | 4/136 (2.9%) | 35/136 (25.7%) | 80/136 (58.8%) |
| Treated, But Not Randomized | 0/16 (0%) | 3/16 (18.8%) | 10/16 (62.5%) |
| Event | Early-start T&E Arm | Late-start T&E Arm | Treated, But Not Randomized |
|---|---|---|---|
| Cerebrovascular accidentNervous system disorders | 1/135 | 0/136 | 2/16 |
| Acute myocardial infarctionCardiac disorders | 0/135 | 1/136 | 1/16 |
| PneumoniaInfections and infestations | 3/135 | 5/136 | 0/16 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 3/135 | 0/136 | 0/16 |
| Cardiac failure congestiveCardiac disorders | 2/135 | 0/136 | 0/16 |
| Abdominal painGastrointestinal disorders | 2/135 | 0/136 | 0/16 |
| Inguinal herniaGastrointestinal disorders | 2/135 | 1/136 | 0/16 |
| Cholecystitis acuteHepatobiliary disorders | 2/135 | 2/136 | 0/16 |
| InfluenzaInfections and infestations | 2/135 | 0/136 | 0/16 |
| Visual acuity reducedEye disorders | 0/135 | 2/136 | 0/16 |
| Event | Early-start T&E Arm | Late-start T&E Arm | Treated, But Not Randomized |
|---|---|---|---|
| Visual acuity reducedEye disorders | 21/135 | 17/136 | 1/16 |
| Conjunctival haemorrhageEye disorders | 20/135 | 18/136 | 0/16 |
| NasopharyngitisInfections and infestations | 18/135 | 17/136 | 0/16 |
| Retinal haemorrhageEye disorders | 4/135 | 6/136 | 2/16 |
| Neovascular age-related macular degenerationEye disorders | 15/135 | 14/136 | 1/16 |
| HypertensionVascular disorders | 13/135 | 11/136 | 0/16 |
| InfluenzaInfections and infestations | 11/135 | 12/136 | 0/16 |
| BlepharitisEye disorders | 2/135 | 11/136 | 0/16 |
| Dry eyeEye disorders | 6/135 | 11/136 | 0/16 |
| Punctate keratitisEye disorders | 10/135 | 5/136 | 1/16 |
All 271 participants were included in the SAF (287), who received any study drug in this study. 269 participants were included in the FAS, excluding 16 participants who were treated but not randomized and 1 participant in each treatment arm from SAF. Of the 269 participants in FAS, 59 participants in total were excluded from the PPS (210).
| Age, Continuous(Years) | Early-start T&E Arm | Late-start T&E Arm | Total |
|---|---|---|---|
| Mean | 76 ± 8.8 | 76.9 ± 8.2 | 76.5 ± 8.5 |
| Sex: Female, Male(Participants) | Early-start T&E Arm | Late-start T&E Arm | Total |
|---|---|---|---|
| Female | 81 | 73 | 154 |
| Male | 54 | 63 | 117 |
| Ethnicity (NIH/OMB)(Participants) | Early-start T&E Arm | Late-start T&E Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 7 | 10 |
| Not Hispanic or Latino | 126 | 122 | 248 |
| Unknown or Not Reported | 6 | 7 | 13 |
| Race (NIH/OMB)(Participants) | Early-start T&E Arm | Late-start T&E Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 131 | 127 | 258 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 8 | 9 |
| Baseline BCVA letters scores (study eye)(letters) | Early-start T&E Arm | Late-start T&E Arm | Total |
|---|---|---|---|
| Mean | 60.2 ± 12.1 | 61.3 ± 10.8 | 60.8 ± 11.4 |
| Baseline CRT(μm) | Early-start T&E Arm | Late-start T&E Arm | Total |
|---|---|---|---|
| Mean | 443.7 ± 120.0 | 448.3 ± 133.1 | 446.0 ± 126.4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Apr 2019, 41 months.
Results were first posted in May 2020, 1 year after primary completion.
Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 41 months is above that.
Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept